Compare RNGR & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNGR | RZLT |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.2M | 352.1M |
| IPO Year | 2017 | 2011 |
| Metric | RNGR | RZLT |
|---|---|---|
| Price | $12.47 | $3.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $19.00 | $10.10 |
| AVG Volume (30 Days) | 208.7K | ★ 1.3M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ 0.52 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.76 | N/A |
| Revenue Next Year | $4.01 | N/A |
| P/E Ratio | $24.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.86 | $1.07 |
| 52 Week High | $18.82 | $11.17 |
| Indicator | RNGR | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 35.79 | 45.14 |
| Support Level | N/A | $3.58 |
| Resistance Level | $16.35 | $4.22 |
| Average True Range (ATR) | 0.69 | 0.35 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 35.20 | 25.94 |
Ranger Energy Services Inc offers high specification mobile rig well services, cased hole wireline services, and ancillary services in the U.S. oil and gas industry. Its services facilitate operations throughout the lifecycle of a well, including the completion, production, maintenance, intervention, workover, and abandonment phases. The company's reportable segments are: High Specification Rigs, Wireline Services, Processing Solutions and Ancillary Services. Maximum revenue is generated from the High Specification Rigs segment, which offers high specification well service rigs and complementary equipment and services to facilitate operations throughout the lifecycle of a well. The high specification rig services consist of well completion support, workovers, and well maintenance services.
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.